ACPU
NVET

Arrowgrass Capital Partners (US)’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-59,868
Closed -$298K – 575
2015
Q2 		$298K Sell
59,868
-207,632
-78% -$1.44M ﹤0.01% 468
2015
Q1 		$2.15M Buy
+267,500
New +$2.53M 0.03% 249

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s NVET Position: Q3 2015 in Review

Arrowgrass Capital Partners (US) sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2015, closing a stake of 59,868 shares — an estimated $298K sold.

Arrowgrass Capital Partners (US) first reported a position in NVET in Q1 2015 and held it in 2 quarters. The position peaked at $2.15M in Q1 2015. 19 funds tracked by Wall St. Rank hold NVET as of Q3 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 59,868 Nexvet Biopharma plc Ordinary Shares shares in Q3 2015, an estimated $298K.
  • Arrowgrass Capital Partners (US) first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Nexvet Biopharma plc Ordinary Shares position peaked at $2.15M in Q1 2015.
  • 19 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2015, filed 16 Nov 2015.